MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xinn.2026.101272

Медицинская библиотека · Innovation (Cambridge (Mass.)) · 2026

Plasma p-Tau217 improves diagnostic accuracy and clinician confidence in cognitive disorder classification.

Huang Yu-Yuan, Li Ling-Ling, Yao Rui-Xin, Dong Jay Zengjun, Gan Yi-Han, Chen Yi-Lin, Chen Ke-Liang, Chen Shu-Fen, Yuan Ming-Yang, Xin Jia-Wei, Wang Jun, Zhang Ya-Ru, Wang YuJing, Yen Tzu-Chen, Cui Mei, Guo Yu, Yu Jin-Tai

СтатьяПеревод пока не подготовлен

Аннотация

The clinical utility of plasma phosphorylated tau at threonine 217 (p-tau217) levels as a diagnostic tool for cognitive disorders in real-world settings remains uncertain. In this cross-sectional retrospective study, 738 consecutive subjects presenting with cognitive complaints at a memory clinic underwent diagnostic evaluation incorporating plasma p-tau217 alongside standard clinical assessments ("tier 2": routine neuroimaging and cognitive testing) and advanced biomarker testing ("tier 1": amyloid positron emission tomography [PET] imaging or cerebrospinal fluid [CSF] analysis). Diagnostic impact and confidence were assessed using clinician surveys. Incorporating plasma p-tau217 into the routine tier 2 diagnostic workup significantly influenced clinical decision-making, leading to diagnostic revisions in 30.2% of cases and improving overall diagnostic confidence from 65.1% to 79.4%. Plasma p-tau217 demonstrated high diagnostic accuracy for Alzheimer's disease (AD), with a sensitivity of 0.88 and a specificity of 0.84. Notably, its specificity was superior to tier 2 diagnoses, whereas its sensitivity did not differ significantly. Plasma p-tau217 also exhibited non-inferior performance to tier 1 approaches in the diagnostic distribution of AD, though with marginally lower diagnostic confidence. For non-AD diagnoses, plasma p-tau217 significantly impacted the classification of synucleinopathies and performed comparably to tier 1 methods. In conclusion, plasma p-tau217 meaningfully impacted diagnostic precision and confidence in subjects presenting to a real-world memory clinic, offering a minimally invasive, cost-effective, and accessible alternative to state-of-the-art examinations. As the global population ages and cognitive disorders become more prevalent, the integration of plasma p-tau217 into routine practice has the potential to streamline diagnostic workflows and enhance the efficient utilization of medical resources.

Для цитирования: Huang Yu-Yuan, Li Ling-Ling, Yao Rui-Xin, Dong Jay Zengjun, Gan Yi-Han, Chen Yi-Lin, Chen Ke-Liang, Chen Shu-Fen, Yuan Ming-Yang, Xin Jia-Wei, Wang Jun, Zhang Ya-Ru, Wang YuJing, Yen Tzu-Chen, Cui Mei, Guo Yu, Yu Jin-Tai. Plasma p-Tau217 improves diagnostic accuracy and clinician confidence in cognitive disorder classification.. Innovation (Cambridge (Mass.)). 2026. DOI: 10.1016/j.xinn.2026.101272.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.